Alebund Pharma, a Shanghai company focused on renal diseases, closed a $54.5 million Series B+ financing round. Four months ago, the company completed a $60 million B round. Alebund will use the proceeds to advance its clinical programs, build a manufacturing facility, research its pre-clinical assets and hire additional staff. Its lead program is a treatment for hyperphosphatemia, currently in a Phase II clinical trial. The B+ round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures. More details.... Share this with colleagues: // //